Pub Date : 2023-03-01DOI: 10.46497/ArchRheumatol.2023.9526
Shanshan Liu, Kai Wang, Ju Li, Yan Liu, Zhongyuan Zhang, Deqian Meng
Objectives: This study aims to investigate the inflammatory effect of the microRNA (miRNA) miR-30e-5p on rheumatoid arthritis (RA) development in RA mice and fibroblast-like synoviocytes (FLS).
Materials and methods: MiR-30e-5p and atlastin GTPase 2 (Atl2) expression in RA tissues and RA-FLS was evaluated using real-time quantitative polymerase chain reaction. The function of miR-30e-5p in inflammation of RA mice and RA-FLS was analyzed by enzyme-linked immunosorbent assay (ELISA) and Western blotting. 5-ethynyl-2'-deoxyuridine (EdU) assay was used to detect RA-FLS proliferation. Luciferase reporter assay was to confirm the interaction between miR-30e-5p and Atl2.
Results: MiR-30e-5p expression was upregulated in the tissues from RA mice. Silencing miR-30e-5p alleviated inflammation in RA mice and RA-FLS. MiR-30e-5p negatively modulated Atl2 expression. Atl2 knockdown exerted a proinflammatory effect on RA-FLS. Atl2 knockdown rescued the inhibitory effect of miR-30e-5p knockdown on proliferation and inflammatory response of RA-FLS.
Conclusion: MiR-30e-5p knockdown inhibited the inflammatory response in RA mice and RA-FLS through Atl2.
{"title":"MiR-30e-5p deficiency exerts an inhibitory effect on inflammation in rheumatoid arthritis via regulating Atl2 expression.","authors":"Shanshan Liu, Kai Wang, Ju Li, Yan Liu, Zhongyuan Zhang, Deqian Meng","doi":"10.46497/ArchRheumatol.2023.9526","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9526","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to investigate the inflammatory effect of the microRNA (miRNA) miR-30e-5p on rheumatoid arthritis (RA) development in RA mice and fibroblast-like synoviocytes (FLS).</p><p><strong>Materials and methods: </strong>MiR-30e-5p and atlastin GTPase 2 (Atl2) expression in RA tissues and RA-FLS was evaluated using real-time quantitative polymerase chain reaction. The function of miR-30e-5p in inflammation of RA mice and RA-FLS was analyzed by enzyme-linked immunosorbent assay (ELISA) and Western blotting. 5-ethynyl-2'-deoxyuridine (EdU) assay was used to detect RA-FLS proliferation. Luciferase reporter assay was to confirm the interaction between miR-30e-5p and Atl2.</p><p><strong>Results: </strong>MiR-30e-5p expression was upregulated in the tissues from RA mice. Silencing miR-30e-5p alleviated inflammation in RA mice and RA-FLS. MiR-30e-5p negatively modulated Atl2 expression. Atl2 knockdown exerted a proinflammatory effect on RA-FLS. Atl2 knockdown rescued the inhibitory effect of miR-30e-5p knockdown on proliferation and inflammatory response of RA-FLS.</p><p><strong>Conclusion: </strong>MiR-30e-5p knockdown inhibited the inflammatory response in RA mice and RA-FLS through Atl2.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":"38 1","pages":"119-128"},"PeriodicalIF":1.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/cc/ArchRheumatol-2023-38-119.PMC10208610.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9529300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.46497/ArchRheumatol.2023.9559
Chrong-Reen Wang, Yi-Shan Tsai, Cheng-Han Lee
Heart involvement with cardiac insufficiency is a cause of early death and is associated with poor prognosis in eosinophilic granulomatosis with polyangiitis (EGPA),1 a disease classified as antineutrophil cytoplasmic antibody-associated vasculitis. Although cyclophosphamide (CYC) is required to induce disease remission in the presence of cardiac insufficiency,2 there is wellknown dosage-related cardiotoxicity in addition to increased risks of infertility, infection, and malignancy.3 Limited efficacy with significant adverse effects of CYC therapy has prompted the search for effective and secure alternative therapeutics in EGPA. Eosinophils play a central role in the pathogenesis, and the activation and recruitment of these cells are mainly mediated by interleukin (IL)-5, a key therapeutic target in EGPA.4 Nevertheless, mepolizumab (MEP), an anti-IL-5 monoclonal antibody, has been suggested in the induction treatment of EGPA with nonsevere diseases, such as asthma and sinonasal manifestations.5 Herein, we report a case of EGPA endomyocarditis with cardiac insufficiency under MEP induction therapy, leading to normalized cardiac dysfunction and disease remission with sparing use of glucocorticoids (GCs).
{"title":"Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis.","authors":"Chrong-Reen Wang, Yi-Shan Tsai, Cheng-Han Lee","doi":"10.46497/ArchRheumatol.2023.9559","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9559","url":null,"abstract":"Heart involvement with cardiac insufficiency is a cause of early death and is associated with poor prognosis in eosinophilic granulomatosis with polyangiitis (EGPA),1 a disease classified as antineutrophil cytoplasmic antibody-associated vasculitis. Although cyclophosphamide (CYC) is required to induce disease remission in the presence of cardiac insufficiency,2 there is wellknown dosage-related cardiotoxicity in addition to increased risks of infertility, infection, and malignancy.3 Limited efficacy with significant adverse effects of CYC therapy has prompted the search for effective and secure alternative therapeutics in EGPA. Eosinophils play a central role in the pathogenesis, and the activation and recruitment of these cells are mainly mediated by interleukin (IL)-5, a key therapeutic target in EGPA.4 Nevertheless, mepolizumab (MEP), an anti-IL-5 monoclonal antibody, has been suggested in the induction treatment of EGPA with nonsevere diseases, such as asthma and sinonasal manifestations.5 Herein, we report a case of EGPA endomyocarditis with cardiac insufficiency under MEP induction therapy, leading to normalized cardiac dysfunction and disease remission with sparing use of glucocorticoids (GCs).","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":"38 1","pages":"159-161"},"PeriodicalIF":1.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/32/ArchRheumatol-2023-38-159.PMC10208624.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9526648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.46497/ArchRheumatol.2022.9239
Serdar Kaymaz, Murat Kavas, Aydın Demiray, Uğur Karasu, Veli Çobankara, Sibel Boğa
Objectives: This study aims to investigate the relationship between the interferon-gamma receptor 1 (IFNGR1) polymorphism and susceptibility to lung sarcoidosis.
Patients and methods: The study included a total of 55 patients (13 males, 42 females; mean age: 46.5±9.1 years; range, 22 to 66 years) with lung sarcoidosis and 28 healthy controls (6 males, 22 females; mean age: 43.9±5.9 years; range 22 to 60 years) selected from the Turkish population. The polymerase chain reaction was used for genotyping of participants to determine single-nucleotide polymorphisms. Hardy-Weinberg equilibrium, which is considered an important tool for detecting genotyping errors, was tested. Allele and genotype frequencies of patients and controls were compared using logistic regression analysis.
Results: The analyses showed no correlation between the tested IFNGR1 single-nucleotide polymorphism (rs2234711) and lung sarcoidosis (p>0.05). The categorization analysis according to the clinical features, laboratory, and radiographic characteristics showed no correlation between the tested polymorphism of IFNGR1 (rs2234711) and these characteristics (p>0.05).
Conclusion: The results of the study showed that the tested gene polymorphism (rs2234711) of IFNGR1 was not associated with lung sarcoidosis. More comprehensive studies are needed to verify our results.
{"title":"Investigation of the relationship between interferon-gamma receptor 1-56C/T gene polymorphism and genetic susceptibility to lung sarcoidosis: A cross-sectional study.","authors":"Serdar Kaymaz, Murat Kavas, Aydın Demiray, Uğur Karasu, Veli Çobankara, Sibel Boğa","doi":"10.46497/ArchRheumatol.2022.9239","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2022.9239","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to investigate the relationship between the interferon-gamma receptor 1 (IFNGR1) polymorphism and susceptibility to lung sarcoidosis.</p><p><strong>Patients and methods: </strong>The study included a total of 55 patients (13 males, 42 females; mean age: 46.5±9.1 years; range, 22 to 66 years) with lung sarcoidosis and 28 healthy controls (6 males, 22 females; mean age: 43.9±5.9 years; range 22 to 60 years) selected from the Turkish population. The polymerase chain reaction was used for genotyping of participants to determine single-nucleotide polymorphisms. Hardy-Weinberg equilibrium, which is considered an important tool for detecting genotyping errors, was tested. Allele and genotype frequencies of patients and controls were compared using logistic regression analysis.</p><p><strong>Results: </strong>The analyses showed no correlation between the tested IFNGR1 single-nucleotide polymorphism (rs2234711) and lung sarcoidosis (p>0.05). The categorization analysis according to the clinical features, laboratory, and radiographic characteristics showed no correlation between the tested polymorphism of IFNGR1 (rs2234711) and these characteristics (p>0.05).</p><p><strong>Conclusion: </strong>The results of the study showed that the tested gene polymorphism (rs2234711) of IFNGR1 was not associated with lung sarcoidosis. More comprehensive studies are needed to verify our results.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":"38 1","pages":"1-8"},"PeriodicalIF":1.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/23/ArchRheumatol-2023-38-001.PMC10208614.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9531839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: This study aimed to analyze the research, publication activities, and perspectives on clinical practices of rheumatology practitioners during the coronavirus disease 2019 (COVID-19) pandemic.
Materials and methods: The survey-based cross-sectional study was designed online and included 24 closed-ended questions. After performing a pilot test and validation of survey, it was conducted among clinicians between September 2021 and December 2021.
Results: One-hundred fifteen clinicians (54 males, 61 females; 78.1% in rheumatology practice for at least five years) responded to the survey. The respondents indicated that they worked in coronavirus-related departments, comprising inpatient service (50.4%), consultancy (42.6%), and outpatient clinic (27.8%). Around 40% of clinicians stated they spent less time on scientific research (43.1%) and clinical learning activities (43.2%), while almost the same proportion of them spent more (41.1% and 45.0%, respectively). This study revealed that 53.5% published at least one paper covering mostly COVID-19 in the scientific citation index (SCI) or SCI-expanded (SCI-E) indexed journals. However, nearly half of them did not have any papers published in the SCI/SCI-E (46.5%) or non-SCI/SCI-E indexed (44.6%) journals. Regarding the perspectives of clinicians about clinical practices, they considered fewer biological (57.0%) and nonbiological (55.0%) drug usage, reported fewer outpatient clinic visits (88.2%), more newly diagnosed rheumatic diseases (62.5%), and more disease exacerbations (31.2%). Most of the clinicians (range, 76.2 to 86.3%) thought they accurately managed their patients during the COVID-19 pandemic.
Conclusion: Clinicians published mostly coronavirus-related papers in the pandemic era, and in the self-assessment, clinicians thought that they correctly manage their patients. In addition, this study reflected the frequency of academic publications and clinicians' work routines during the pandemic.
{"title":"Academic publication activities and perspectives of rheumatology practitioners in the COVID-19 pandemic.","authors":"Abdulvahap Kahveci, Alper Gümüştepe, Nurhan Güven, İsmihan Sunar, Şebnem Ataman","doi":"10.46497/ArchRheumatol.2023.9957","DOIUrl":"10.46497/ArchRheumatol.2023.9957","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to analyze the research, publication activities, and perspectives on clinical practices of rheumatology practitioners during the coronavirus disease 2019 (COVID-19) pandemic.</p><p><strong>Materials and methods: </strong>The survey-based cross-sectional study was designed online and included 24 closed-ended questions. After performing a pilot test and validation of survey, it was conducted among clinicians between September 2021 and December 2021.</p><p><strong>Results: </strong>One-hundred fifteen clinicians (54 males, 61 females; 78.1% in rheumatology practice for at least five years) responded to the survey. The respondents indicated that they worked in coronavirus-related departments, comprising inpatient service (50.4%), consultancy (42.6%), and outpatient clinic (27.8%). Around 40% of clinicians stated they spent less time on scientific research (43.1%) and clinical learning activities (43.2%), while almost the same proportion of them spent more (41.1% and 45.0%, respectively). This study revealed that 53.5% published at least one paper covering mostly COVID-19 in the scientific citation index (SCI) or SCI-expanded (SCI-E) indexed journals. However, nearly half of them did not have any papers published in the SCI/SCI-E (46.5%) or non-SCI/SCI-E indexed (44.6%) journals. Regarding the perspectives of clinicians about clinical practices, they considered fewer biological (57.0%) and nonbiological (55.0%) drug usage, reported fewer outpatient clinic visits (88.2%), more newly diagnosed rheumatic diseases (62.5%), and more disease exacerbations (31.2%). Most of the clinicians (range, 76.2 to 86.3%) thought they accurately managed their patients during the COVID-19 pandemic.</p><p><strong>Conclusion: </strong>Clinicians published mostly coronavirus-related papers in the pandemic era, and in the self-assessment, clinicians thought that they correctly manage their patients. In addition, this study reflected the frequency of academic publications and clinicians' work routines during the pandemic.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":" ","pages":"611-619"},"PeriodicalIF":1.1,"publicationDate":"2023-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44923803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-15eCollection Date: 2023-12-01DOI: 10.46497/ArchRheumatol.2023.9806
Lale Altan, Burcu Metin Ökmen, Tiraje Tuncer, Dilşad Sindel, Hasan Fatih Çay, Simin Hepgüler, Selda Sarıkaya, Figen Ayhan, Ajda Bal, Meral Bilgilisoy, Erhan Çapkın, Lale Cerrahoğlu, Remzi Çevik, Deniz Dülgeroğlu, Berrin Durmaz, Tuncay Duruöz, Gülcan Gürer, Savaş Gürsoy, Sami Hizmetli, Cahit Kaçar, Ece Kaptanoğlu, Hilal Ecesoy, Meltem Melikoğlu, Kemal Nas, Hakan Nur, Şüheda Özçakır, Nilay Şahin, Özlem Şahin, Merih Sarıdoğan, Ömer Faruk Şendur, İlhan Sezer, Gülnur Taşçı Bozbaş, Canan Tıkız, Hatice Uğurlu
Objectives: The purpose of the study was to contribute further to this debated topic by investigating the correlation of magnetic resonance imaging (MRI) findings with the clinical picture in lumbar spondylosis patients.
Patients and methods: This multicenter retrospective study (as part of the epidemiological project of the TLAR-OASG [Turkish League Against Rheumatism-Osteoarthritis Study Group]) included 514 patients (101 males, 413 females; mean age: 63.6±10.8 years; range, 40 to 85 years) who were diagnosed as lumbar spondylosis by clinical examination and direct X-ray between December 2016 and June 2018. Demographic characteristics of patients, Visual Analog Scale for pain, presence of radiating pain, Roland-Morris disability questionnaire, straight leg raise test, deep tendon reflexes, neurogenic intermittent claudication symptoms, any decrease of muscle strength, and abnormality of sensation were recorded. Lumbar MRI findings of the patients were recorded as positive or negative in terms of disc herniation, intervertebral disc degeneration, root compression, osteophytes, spinal stenosis. Statistical analysis was done to assess the correlation between the clinical symptoms, physical examination, and MRI findings.
Results: Correlation analysis of the MRI results and the clinical findings showed a significant correlation between straight leg raise test and root compression (p<0.001, r=0.328) and a significant correlation between neurogenic intermittent claudication and spinal stenosis (p<0.001, r=0.376). Roland-Morris disability questionnaire had a significant correlation with all MRI findings (p<0.05, r<0.200).
Conclusion: The results of this study corroborate the notion that diligent patient history and physical examination are more valuable than MRI findings, even though a higher incidence of abnormal MRI findings have been obtained in patients with disability and dermatomal radiating pain.
{"title":"Correlation of clinical signs and magnetic resonance imaging findings in patients with lumbar spondylosis.","authors":"Lale Altan, Burcu Metin Ökmen, Tiraje Tuncer, Dilşad Sindel, Hasan Fatih Çay, Simin Hepgüler, Selda Sarıkaya, Figen Ayhan, Ajda Bal, Meral Bilgilisoy, Erhan Çapkın, Lale Cerrahoğlu, Remzi Çevik, Deniz Dülgeroğlu, Berrin Durmaz, Tuncay Duruöz, Gülcan Gürer, Savaş Gürsoy, Sami Hizmetli, Cahit Kaçar, Ece Kaptanoğlu, Hilal Ecesoy, Meltem Melikoğlu, Kemal Nas, Hakan Nur, Şüheda Özçakır, Nilay Şahin, Özlem Şahin, Merih Sarıdoğan, Ömer Faruk Şendur, İlhan Sezer, Gülnur Taşçı Bozbaş, Canan Tıkız, Hatice Uğurlu","doi":"10.46497/ArchRheumatol.2023.9806","DOIUrl":"10.46497/ArchRheumatol.2023.9806","url":null,"abstract":"<p><strong>Objectives: </strong>The purpose of the study was to contribute further to this debated topic by investigating the correlation of magnetic resonance imaging (MRI) findings with the clinical picture in lumbar spondylosis patients.</p><p><strong>Patients and methods: </strong>This multicenter retrospective study (as part of the epidemiological project of the TLAR-OASG [Turkish League Against Rheumatism-Osteoarthritis Study Group]) included 514 patients (101 males, 413 females; mean age: 63.6±10.8 years; range, 40 to 85 years) who were diagnosed as lumbar spondylosis by clinical examination and direct X-ray between December 2016 and June 2018. Demographic characteristics of patients, Visual Analog Scale for pain, presence of radiating pain, Roland-Morris disability questionnaire, straight leg raise test, deep tendon reflexes, neurogenic intermittent claudication symptoms, any decrease of muscle strength, and abnormality of sensation were recorded. Lumbar MRI findings of the patients were recorded as positive or negative in terms of disc herniation, intervertebral disc degeneration, root compression, osteophytes, spinal stenosis. Statistical analysis was done to assess the correlation between the clinical symptoms, physical examination, and MRI findings.</p><p><strong>Results: </strong>Correlation analysis of the MRI results and the clinical findings showed a significant correlation between straight leg raise test and root compression (p<0.001, r=0.328) and a significant correlation between neurogenic intermittent claudication and spinal stenosis (p<0.001, r=0.376). Roland-Morris disability questionnaire had a significant correlation with all MRI findings (p<0.05, r<0.200).</p><p><strong>Conclusion: </strong>The results of this study corroborate the notion that diligent patient history and physical examination are more valuable than MRI findings, even though a higher incidence of abnormal MRI findings have been obtained in patients with disability and dermatomal radiating pain.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":" ","pages":"512-520"},"PeriodicalIF":1.1,"publicationDate":"2023-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45846016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-03eCollection Date: 2023-09-01DOI: 10.46497/ArchRheumatol.2023.9386
Cristiano Carvalho, Glaucia Helena Gonçalves, Luiz Fernando Approbato Selistre, Marina Petrella, Tatiana De Oliveira Sato, Paula Regina Mendes Da Silva Serrão, Stela Márcia Mattiello
Objectives: This study aimed to investigate the association between ankle torque and performance-based tests, self-reported pain, and physical function in patients with knee osteoarthritis (OA).
Patients and methods: The cross-sectional study was conducted with 39 individuals (24 females, 15 males; mean age: 57.3±6.2 years; range, 40 to 65 years) with knee OA between January 2014 and July 2015. Ankle torque was determined using an isokinetic dynamometer. The 40-m fast-paced walk test and a stair climb test were used to assess functional performance. Self-reported pain and physical function were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pearson's correlation coefficients were calculated to test correlations between the dependent variables (40-m fast-paced walk test, stair climb test, WOMAC pain and physical function domains, sex, age, body mass index, and radiologic evidence of OA) and the independent variables (mean plantar flexor torque and dorsiflexor peak torque). A multiple linear regression analysis was applied to quantify the association between the dependent and independent variables.
Results: Dorsiflexor and plantar flexor peak torques in the concentric and eccentric modes were negatively correlated with the 40-m fast-paced walk and stair climb tests (r=-0.33 to -0.51, p≤0.05). A negative correlation was found between concentric plantar flexor torque and the WOMAC physical function score (r=-0.35, p=0.03). No correlation was found between ankle torques and the WOMAC pain score (p>0.05). The multiple linear regression analysis showed that the eccentric plantar flexor and dorsiflexor torques were significantly associated with the stair climb test (β=-0.001, 95% confidence interval [CI]: -0.001 to 0.000, p=0.03, and β=-0.002, 95% CI: -0.004 to 0.000, p=0.05, respectively). No significant associations were found between concentric plantar flexor and dorsiflexor torques and the stair climb test (p>0.05). No significant associations were found between the ankle torques and the 40-m fast-paced walk test and WOMAC physical function (p>0.05).
Conclusion: Ankle torque plays an important role in functional performance. Thus, ankle torque deficit, especially eccentric plantar flexor and dorsiflexor torques, may exert a negative influence on stair climbing performance in patients with knee osteoarthritis.
{"title":"Association between ankle torque and performance-based tests, self-reported pain, and physical function in patients with knee osteoarthritis.","authors":"Cristiano Carvalho, Glaucia Helena Gonçalves, Luiz Fernando Approbato Selistre, Marina Petrella, Tatiana De Oliveira Sato, Paula Regina Mendes Da Silva Serrão, Stela Márcia Mattiello","doi":"10.46497/ArchRheumatol.2023.9386","DOIUrl":"10.46497/ArchRheumatol.2023.9386","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the association between ankle torque and performance-based tests, self-reported pain, and physical function in patients with knee osteoarthritis (OA).</p><p><strong>Patients and methods: </strong>The cross-sectional study was conducted with 39 individuals (24 females, 15 males; mean age: 57.3±6.2 years; range, 40 to 65 years) with knee OA between January 2014 and July 2015. Ankle torque was determined using an isokinetic dynamometer. The 40-m fast-paced walk test and a stair climb test were used to assess functional performance. Self-reported pain and physical function were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pearson's correlation coefficients were calculated to test correlations between the dependent variables (40-m fast-paced walk test, stair climb test, WOMAC pain and physical function domains, sex, age, body mass index, and radiologic evidence of OA) and the independent variables (mean plantar flexor torque and dorsiflexor peak torque). A multiple linear regression analysis was applied to quantify the association between the dependent and independent variables.</p><p><strong>Results: </strong>Dorsiflexor and plantar flexor peak torques in the concentric and eccentric modes were negatively correlated with the 40-m fast-paced walk and stair climb tests (r=-0.33 to -0.51, p≤0.05). A negative correlation was found between concentric plantar flexor torque and the WOMAC physical function score (r=-0.35, p=0.03). No correlation was found between ankle torques and the WOMAC pain score (p>0.05). The multiple linear regression analysis showed that the eccentric plantar flexor and dorsiflexor torques were significantly associated with the stair climb test (β=-0.001, 95% confidence interval [CI]: -0.001 to 0.000, p=0.03, and β=-0.002, 95% CI: -0.004 to 0.000, p=0.05, respectively). No significant associations were found between concentric plantar flexor and dorsiflexor torques and the stair climb test (p>0.05). No significant associations were found between the ankle torques and the 40-m fast-paced walk test and WOMAC physical function (p>0.05).</p><p><strong>Conclusion: </strong>Ankle torque plays an important role in functional performance. Thus, ankle torque deficit, especially eccentric plantar flexor and dorsiflexor torques, may exert a negative influence on stair climbing performance in patients with knee osteoarthritis.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":" ","pages":"387-396"},"PeriodicalIF":1.1,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42625528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: This study aimed to evaluate the risk of tuberculosis (TB) disease in children receiving biological agents for rheumatologic diseases, focusing on appropriate screening tests in a high-priority country for TB control.
Patients and methods: One hundred nine children (56 females, 53 males; range, 3.4 to 16.2 years) who received any biological agent for rheumatologic diseases for more than two years between May 2012 and October 2021 were included in this retrospective study. Patients were screened for TB infection using tuberculin skin test (TST) or interferon-gamma release assay (IGRA). Following the initial evaluation, patients were clinically examined for TB every three months by a comprehensive medical history and physical examination, and every 12 months using TST or IGRA.
Results: At the initiation of the biological agent, the patients' mean age was 12.4±4.5 years. The average follow-up duration was 3.6±1.3 years (range, 2.6 to 10.2 years) for patients treated with biological agents. Each patient had a documented Bacillus Calmette-Guérin vaccination. Before the initiating of therapy, TST was performed alone in 45 (41.3%) patients and in combination with IGRA in 64 (58.7%) patients. In the 64 patients who underwent both TST and IGRA, IGRA revealed nine (14.1%) positive results. Six (66.7%) of these nine patients, however, had negative baseline TST. Four (7.3%) of the 55 individuals whose initial IGRA results were negative also had positive TST results. Overall, no TB disease was observed after a follow-up period.
Conclusion: This study reveals that biological agents were not associated with an increased risk of TB disease in closely monitored children. Additionally, the concomitant use of TST and IGRA for screening of TB is reasonable in patients receiving biological agents.
{"title":"Risk of tuberculosis in children with rheumatologic diseases treated with biological agents: A cross-sectional cohort study.","authors":"Nuri Bayram, Özge Altuğ Gücenmez, Balahan Makay, Elif Kıymet, Elif Böncüoğlu, Şahika Şahinkaya, Yelda Sorguç, Aybüke Akaslan Kara, Kamile Ötiken Arıkan, İlker Devrim","doi":"10.46497/ArchRheumatol.2023.9900","DOIUrl":"10.46497/ArchRheumatol.2023.9900","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the risk of tuberculosis (TB) disease in children receiving biological agents for rheumatologic diseases, focusing on appropriate screening tests in a high-priority country for TB control.</p><p><strong>Patients and methods: </strong>One hundred nine children (56 females, 53 males; range, 3.4 to 16.2 years) who received any biological agent for rheumatologic diseases for more than two years between May 2012 and October 2021 were included in this retrospective study. Patients were screened for TB infection using tuberculin skin test (TST) or interferon-gamma release assay (IGRA). Following the initial evaluation, patients were clinically examined for TB every three months by a comprehensive medical history and physical examination, and every 12 months using TST or IGRA.</p><p><strong>Results: </strong>At the initiation of the biological agent, the patients' mean age was 12.4±4.5 years. The average follow-up duration was 3.6±1.3 years (range, 2.6 to 10.2 years) for patients treated with biological agents. Each patient had a documented Bacillus Calmette-Guérin vaccination. Before the initiating of therapy, TST was performed alone in 45 (41.3%) patients and in combination with IGRA in 64 (58.7%) patients. In the 64 patients who underwent both TST and IGRA, IGRA revealed nine (14.1%) positive results. Six (66.7%) of these nine patients, however, had negative baseline TST. Four (7.3%) of the 55 individuals whose initial IGRA results were negative also had positive TST results. Overall, no TB disease was observed after a follow-up period.</p><p><strong>Conclusion: </strong>This study reveals that biological agents were not associated with an increased risk of TB disease in closely monitored children. Additionally, the concomitant use of TST and IGRA for screening of TB is reasonable in patients receiving biological agents.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":" ","pages":"549-555"},"PeriodicalIF":1.1,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48687455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-03eCollection Date: 2023-09-01DOI: 10.46497/ArchRheumatol.2023.9927
Pervin Elvan Tokgun, Nedim Karagenc, Uğur Karasu, Onur Tokgun, Samet Turel, Aydın Demiray, Hakan Akca, Selçuk Yüksel
Objectives: This study aimed to reveal the genetic background of patients in the two-generation family suffering from rheumatoid arthritis, psoriatic arthropathy pain, scratches, and bruises.
Patients and methods: A clinical exome sequencing analysis was performed in 10 individuals in the same family using the Sophia Genetics clinical exome solution kit.
Results: A novel V194L mutation in the TMEM173 gene was identified in three members of the family. Two of the family members were treated with the JAK3 inhibitor tofacitinib and recovered completely one month after the treatment.
Conclusion: The V194L mutation was reported for the first time in this study, and a positive response was achieved with tofacitinib.
{"title":"Treatment of STING-associated vasculopathy with onset in infancy in patients carrying a novel mutation in the TMEM173 gene with the JAK3-inhibitor tofacitinib.","authors":"Pervin Elvan Tokgun, Nedim Karagenc, Uğur Karasu, Onur Tokgun, Samet Turel, Aydın Demiray, Hakan Akca, Selçuk Yüksel","doi":"10.46497/ArchRheumatol.2023.9927","DOIUrl":"10.46497/ArchRheumatol.2023.9927","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to reveal the genetic background of patients in the two-generation family suffering from rheumatoid arthritis, psoriatic arthropathy pain, scratches, and bruises.</p><p><strong>Patients and methods: </strong>A clinical exome sequencing analysis was performed in 10 individuals in the same family using the Sophia Genetics clinical exome solution kit.</p><p><strong>Results: </strong>A novel V194L mutation in the TMEM173 gene was identified in three members of the family. Two of the family members were treated with the JAK3 inhibitor tofacitinib and recovered completely one month after the treatment.</p><p><strong>Conclusion: </strong>The V194L mutation was reported for the first time in this study, and a positive response was achieved with tofacitinib.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":" ","pages":"461-467"},"PeriodicalIF":1.1,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48182296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-02eCollection Date: 2023-09-01DOI: 10.46497/ArchRheumatol.2023.9676
Fatih Taştekin, Meltem Taşbakan, Candan Çiçek, Mehmet Soylu, Figen Yargucu Zihni
Objectives: In this study, we report the immune response to the BNT162b2 vaccine and CoronaVac vaccine after a two-dose vaccination and the effects of conventional drugs, immunosuppressive drugs, and new-generation therapies on vaccine responses in patients with rheumatic and musculoskeletal diseases (RMDs).
Patients and methods: This is a prospective observational study conducted with 94 patients (65 males, 29 females; mean age: 42.7±12.1 years; range, 19 to 69 years) between May 2021 and January 2022. The immunogenicity of the two-dose regimens of the BNT162b2 and CoronaVac vaccines in adult patients with RMD was analyzed according to disease and treatments. Serum immunoglobulin G antibody levels against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike proteins were measured four weeks after the second dose of vaccines.
Results: Patients on regimens including mycophenolate, rituximab, and steroids were less likely to develop an antibody response (p=0.001, p=0.06, and p=0.001, respectively). Impairment of vaccine response by other conventional disease-modifying antirheumatic drugs and by anti-tumor necrosis factor treatments was not shown. Younger participants appeared more likely to develop an antibody response. The CoronaVac vaccine was less likely to develop an antibody response compared to the BNT162b2 vaccine (p=0.002). Systemic lupus erythematosus and vasculitis had the lowest antibody titers compared to other RMDs.
Conclusion: Patients receiving mycophenolate mofetil, rituximab, and steroids should be warned about the risk of a suboptimal vaccine response. If possible, vaccination strategies should be changed, and the dose modification of drugs should be made during the vaccination. Further studies are required to determine the responses to SARS-CoV-2 vaccination and optimization of vaccine response in patients with RMDs.
{"title":"Efficacy of coronavirus disease 2019 vaccines in patients with rheumatic diseases.","authors":"Fatih Taştekin, Meltem Taşbakan, Candan Çiçek, Mehmet Soylu, Figen Yargucu Zihni","doi":"10.46497/ArchRheumatol.2023.9676","DOIUrl":"10.46497/ArchRheumatol.2023.9676","url":null,"abstract":"<p><strong>Objectives: </strong>In this study, we report the immune response to the BNT162b2 vaccine and CoronaVac vaccine after a two-dose vaccination and the effects of conventional drugs, immunosuppressive drugs, and new-generation therapies on vaccine responses in patients with rheumatic and musculoskeletal diseases (RMDs).</p><p><strong>Patients and methods: </strong>This is a prospective observational study conducted with 94 patients (65 males, 29 females; mean age: 42.7±12.1 years; range, 19 to 69 years) between May 2021 and January 2022. The immunogenicity of the two-dose regimens of the BNT162b2 and CoronaVac vaccines in adult patients with RMD was analyzed according to disease and treatments. Serum immunoglobulin G antibody levels against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike proteins were measured four weeks after the second dose of vaccines.</p><p><strong>Results: </strong>Patients on regimens including mycophenolate, rituximab, and steroids were less likely to develop an antibody response (p=0.001, p=0.06, and p=0.001, respectively). Impairment of vaccine response by other conventional disease-modifying antirheumatic drugs and by anti-tumor necrosis factor treatments was not shown. Younger participants appeared more likely to develop an antibody response. The CoronaVac vaccine was less likely to develop an antibody response compared to the BNT162b2 vaccine (p=0.002). Systemic lupus erythematosus and vasculitis had the lowest antibody titers compared to other RMDs.</p><p><strong>Conclusion: </strong>Patients receiving mycophenolate mofetil, rituximab, and steroids should be warned about the risk of a suboptimal vaccine response. If possible, vaccination strategies should be changed, and the dose modification of drugs should be made during the vaccination. Further studies are required to determine the responses to SARS-CoV-2 vaccination and optimization of vaccine response in patients with RMDs.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":"1 1","pages":"419-428"},"PeriodicalIF":1.1,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41815357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01eCollection Date: 2023-09-01DOI: 10.46497/ArchRheumatol.2023.9547
Hong Chen, Jun Tang, Juhua Liang, Dan Huang, Chunfeng Pan, Sha Liu, Xiuri Du, Liju Tao
Objectives: This study was implemented to reveal the expression and the clinical correlation of matrix metalloproteinases (MPSs) with connective tissue disease (CTD) complicated with interstitial lung disease (ILD).
Patients and methods: This clinical study was conducted with 260 patients (151 males, 109 females; mean age: 47.3±12.5 years; range, 29 to 67 years) between October 2019 and October 2020. Among the subjects, 100 were CTD patients (CTD group), 80 were CTD patients with ILD (CTD-ILD group) and 80 were healthy individuals (control group). The MMP-2, -3, -7, and -9 levels in the serum of the three groups were detected by enzyme-linked immunosorbent assay.
Results: Serum levels of MMP-3, -7, and -9 in the CTD-ILD group were higher, while the MMP-2 level was lower than those in the CTD group and the control group. The MMP-7 level in the serum of the CTD-ILD group was positively related to C-reactive protein, erythrocyte sedimentation rate, and rheumatoid factor and negatively correlated with immunoglobulin G and complement 3. The MMP-7 expression in the serum was positively correlated with forced expiratory volume in one second (FEV1%), FEV1/forced expiratory volume (FVC), and FVC in CTD-ILD patients. Pearson statistical analysis revealed that there was a significant positive correlation between the MMP-7 expression and the percentage of B cells in the serum of CTD-ILD patients.
Conclusion: Expressions of MMP-3, -7, and -9 are significantly increased in the serum of patients with CTD and related interstitial lung lesions, and the high expression of MMP-7 indicates dynamic lung lesions, which is possible to be used as a possible biomarker for early diagnosis and assessment of disease progression.
{"title":"Clinical association study on the matrix metalloproteinase expression in the serum of patients with connective tissue disease complicated with interstitial lung disease.","authors":"Hong Chen, Jun Tang, Juhua Liang, Dan Huang, Chunfeng Pan, Sha Liu, Xiuri Du, Liju Tao","doi":"10.46497/ArchRheumatol.2023.9547","DOIUrl":"10.46497/ArchRheumatol.2023.9547","url":null,"abstract":"<p><strong>Objectives: </strong>This study was implemented to reveal the expression and the clinical correlation of matrix metalloproteinases (MPSs) with connective tissue disease (CTD) complicated with interstitial lung disease (ILD).</p><p><strong>Patients and methods: </strong>This clinical study was conducted with 260 patients (151 males, 109 females; mean age: 47.3±12.5 years; range, 29 to 67 years) between October 2019 and October 2020. Among the subjects, 100 were CTD patients (CTD group), 80 were CTD patients with ILD (CTD-ILD group) and 80 were healthy individuals (control group). The MMP-2, -3, -7, and -9 levels in the serum of the three groups were detected by enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Serum levels of MMP-3, -7, and -9 in the CTD-ILD group were higher, while the MMP-2 level was lower than those in the CTD group and the control group. The MMP-7 level in the serum of the CTD-ILD group was positively related to C-reactive protein, erythrocyte sedimentation rate, and rheumatoid factor and negatively correlated with immunoglobulin G and complement 3. The MMP-7 expression in the serum was positively correlated with forced expiratory volume in one second (FEV1%), FEV1/forced expiratory volume (FVC), and FVC in CTD-ILD patients. Pearson statistical analysis revealed that there was a significant positive correlation between the MMP-7 expression and the percentage of B cells in the serum of CTD-ILD patients.</p><p><strong>Conclusion: </strong>Expressions of MMP-3, -7, and -9 are significantly increased in the serum of patients with CTD and related interstitial lung lesions, and the high expression of MMP-7 indicates dynamic lung lesions, which is possible to be used as a possible biomarker for early diagnosis and assessment of disease progression.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":" ","pages":"367-374"},"PeriodicalIF":1.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45830705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}